AVBP (ArriVent BioPharma) Other Stockholders Equity : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Other Stockholders Equity?

ArriVent BioPharma's Other Stockholders Equity for the quarter that ended in Dec. 2024 was $0.00 Mil.

ArriVent BioPharma Other Stockholders Equity Historical Data

The historical data trend for ArriVent BioPharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Other Stockholders Equity Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Stockholders Equity

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Stockholders Equity	Get a 7-Day Free Trial						-	-	-	-	-

ArriVent BioPharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

ArriVent BioPharma Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.